Septerna, Inc. (SEPN)
NASDAQ:SEPN
Top Page
Septerna, Inc.
(NASDAQ:SEPN)
Select Model
Select Model
Rating:49Neutral
Price Target:
$23.00
▼(-1.46% Downside)
Action:ReiteratedDate:04/13/26
The score is held down primarily by ongoing losses and inconsistent profitability despite better 2025 cash flow and revenue growth. Technical indicators also point to bearish momentum (below key moving averages and negative MACD). Offsetting these are positive early-stage clinical milestones, but valuation remains challenging with a negative P/E and no dividend.
Positive Factors
Improved cash generation
The large positive operating and free cash flow in 2025 provides a durable internal funding source to advance clinical programs without immediate reliance on equity markets. Sustained positive cash generation can lengthen runway, reduce dilution risk, and support multi-year R&D investment if maintained.
Negative Factors
Persistent net losses
Material ongoing losses and negative margins indicate the company has not yet reached sustainable earnings power. Continued multi-year losses can compress returns, keep ROE negative, and force financing or milestone-dependent outcomes, limiting long-term free-cash-flow visibility absent product approvals.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved cash generation
The large positive operating and free cash flow in 2025 provides a durable internal funding source to advance clinical programs without immediate reliance on equity markets. Sustained positive cash generation can lengthen runway, reduce dilution risk, and support multi-year R&D investment if maintained.
Read all positive factors
Septerna, Inc. (SEPN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05B
Dividend YieldN/A
Average Volume (3M)274.57K
Price to Earnings (P/E)―
Beta (1Y)2.15
Revenue Growth2147.20%
EPS Growth-269.99%
CountryUS
Employees75
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.24
Shares Outstanding44,906,376
10 Day Avg. Volume232,179
30 Day Avg. Volume274,574
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue21.47
Enterprise Value/Gross Profit21.47
Enterprise Value/Ebitda-12.46
Forecast
1Y Price Target
$37.27Price Target Upside59.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.58
Revenue Forecast (FY)$68.30M
Septerna, Inc. Business Overview & Revenue Model
Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The c...
How the Company Makes Money
null...
Septerna, Inc. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
67
Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 45.95M | 1.07M | 151.00K | 0.00 |
| Gross Profit | 45.95M | 1.07M | 151.00K | 0.00 |
| EBITDA | -79.19M | -79.42M | -44.70M | -27.39M |
| Net Income | -48.88M | -71.80M | 4.18M | -27.68M |
Balance Sheet | ||||
| Total Assets | 596.19M | 456.55M | 130.87M | 36.12M |
| Cash, Cash Equivalents and Short-Term Investments | 391.09M | 350.92M | 88.48M | 30.61M |
| Total Debt | 23.63M | 25.48M | 12.57M | 710.00K |
| Total Liabilities | 214.26M | 36.51M | 169.24M | 80.32M |
| Stockholders Equity | 381.93M | 420.05M | -38.37M | -44.20M |
Cash Flow | ||||
| Free Cash Flow | 109.67M | -69.57M | -41.60M | -24.59M |
| Operating Cash Flow | 110.19M | -67.47M | -38.72M | -23.30M |
| Investing Cash Flow | -229.35M | -160.60M | 22.12M | -1.29M |
| Financing Cash Flow | 1.69M | 377.78M | 74.52M | 30.05M |
Septerna, Inc. Technical Analysis
Negative
23.34
Price Trends
26.09
Negative
26.28
Negative
20.99
Positive
Market Momentum
-0.66
Negative
40.25
Neutral
29.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEPN, the sentiment is Negative. The current price of 23.34 is below the 20-day moving average (MA) of 24.26, below the 50-day MA of 26.09, and above the 200-day MA of 20.99, indicating a neutral trend. The MACD of -0.66 indicates Negative momentum. The RSI at 40.25 is Neutral, neither overbought nor oversold. The STOCH value of 29.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SEPN.
Septerna, Inc. Risk Analysis
Septerna, Inc. disclosed 89 risk factors in its most recent earnings report. Septerna, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Septerna, Inc. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $849.63M | 8.89 | 46.03% | ― | 27.12% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | $2.22B | -8.98 | -23.43% | ― | 31.11% | -46.75% | |
53 Neutral | $786.63M | -3.61 | -51.07% | ― | -30.56% | 48.79% | |
52 Neutral | $770.24M | -3.27 | -102.59% | ― | ― | -5.18% | |
49 Neutral | $1.05B | -25.24 | -12.63% | ― | 2147.20% | -269.99% | |
41 Neutral | $94.02M | -3.72 | 264.70% | ― | -58.17% | -116.24% |
* Technology Sector Average
SEPN
Septerna, Inc.
24.13
17.84
283.62%
TBPH
Theravance Biopharma
16.60
7.97
92.35%
KURA
Kura Oncology
9.14
3.11
51.58%
GOSS
Gossamer Bio
0.43
-0.40
-48.01%
MRVI
Maravai Lifesciences Holdings
3.28
1.55
89.60%
DAWN
Day One Biopharmaceuticals
21.46
14.27
198.47%
Septerna, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Septerna Begins Phase 1 Trial of Oral SEP-479
Positive
Apr 13, 2026
On April 13, 2026, Septerna, Inc. reported that it has begun dosing participants in a Phase 1 clinical trial of SEP-479, an oral small molecule parathyroid hormone 1 receptor agonist being developed to treat hypoparathyroidism. The program targets...
Business Operations and StrategyProduct-Related Announcements
Septerna Advances SEP-631 After Positive Phase 1 Results
Positive
Mar 2, 2026
On March 1, 2026, Septerna reported positive Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2 being developed for chronic spontaneous urticaria and other mast cell-driven diseases. In healthy volunteers, SEP-631 was we...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.